Rudolph Navari to Treatment Outcome
This is a "connection" page, showing publications Rudolph Navari has written about Treatment Outcome.
Connection Strength
0.231
-
Real-World Treatment Outcomes, Healthcare Resource Use, and Costs Associated with Antiemetics Among Cancer Patients on Cisplatin-Based Chemotherapy. Adv Ther. 2023 07; 40(7):3217-3226.
Score: 0.089
-
Unscheduled hydrations: redefining complete response in chemotherapy-induced nausea and vomiting studies. Future Oncol. 2020 Aug; 16(24):1863-1872.
Score: 0.073
-
Treatment of depressive symptoms in patients with early stage breast cancer undergoing adjuvant therapy. Breast Cancer Res Treat. 2008 Nov; 112(1):197-201.
Score: 0.031
-
Accurate Therapeutic Response Assessment of Pancreatic Ductal Adenocarcinoma Using Quantitative Dynamic Contrast-Enhanced Magnetic Resonance Imaging With a Point-of-Care Perfusion Phantom: A Pilot Study. Invest Radiol. 2019 01; 54(1):16-22.
Score: 0.016
-
Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy. Eur J Cancer. 2016 Apr; 57:23-30.
Score: 0.013
-
A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients: a Hoosier Oncology Group study. Cancer Invest. 2004; 22(3):383-8.
Score: 0.006
-
Treatment of cancer-associated hypercalcemia. Double-blind comparison of rapid and slow intravenous infusion regimens of pamidronate disodium and saline alone. Arch Intern Med. 1994 Sep 12; 154(17):1935-44.
Score: 0.003